FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170816474> ?p ?o ?g. }

• W2170816474 endingPage "1740" @default.
• W2170816474 startingPage "1735" @default.
• W2170816474 abstract "More than 71,000 relatives of type 1 diabetic patients have been screened for cytoplasmic islet cell antibodies (ICAs), GAD65 autoantibodies (GAAs), and ICA512 autoantibodies (ICA512AAs). Among those 71,148 relatives, 2,448 were cytoplasmic ICA+, and the remainder were ICA-. Of the ICA+ group, 1,229 (50.2%) were positive for GAAs and/or ICA512AAs. Among ICA- relatives, 1,897 (2.76%) were positive for GAAs and/or ICA512AAs. Given the large number of relatives positive for cytoplasmic ICA and negative for biochemically determined autoantibodies, and the converse, we analyzed the proportion of ICA+ relatives found eligible to participate in the intervention phase of Diabetes Prevention Trial-Type 1 (DPT-1). To be eligible for the parenteral insulin DPT-1 trial, a relative had to have first-phase insulin secretion below the 1st percentile of cut-points (for parents) or below the 10th percentile (for siblings and offspring). To be eligible for the oral insulin trial, a relative had to have first-phase insulin secretion above cut-points (>1st percentile for parents, >10th percentile for siblings/offspring) and be positive for anti-insulin autoantibodies. For both trials, DQB1*0602 was an exclusion criteria, cytoplasmic ICA positivity had to be confirmed, and an oral glucose tolerance test had to result in nondiabetic levels. Of 572 relatives found to be eligible for trial entry, 442 (77.3%) were positive for GAAs and/or ICA512AAs, although overall only 50.2% of ICA+ relatives were positive for GAAs and/or ICA512AAs. The positive predictive value for trial eligibility for ICA+ relatives with GAAs or ICA512AAs who completed staging was 51.0%. In contrast, only 11.9% of ICA+ but GAA- and ICA512AA- relatives were found to be eligible by DPT criteria for trial entry. Positivity for biochemically determined autoantibodies among cytoplasmic antibody-positive relatives is associated with eligibility for the DPT-1 study." @default.
• W2170816474 created "2016-06-24" @default.
• W2170816474 creator A5005436471 @default.
• W2170816474 creator A5038398583 @default.
• W2170816474 creator A5038424501 @default.
• W2170816474 creator A5057008464 @default.
• W2170816474 creator A5062927758 @default.
• W2170816474 creator A5066701655 @default.
• W2170816474 creator A5070865625 @default.
• W2170816474 creator A5084625995 @default.
• W2170816474 date "2001-08-01" @default.
• W2170816474 modified "2023-10-16" @default.
• W2170816474 title "Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial−Type 1" @default.
• W2170816474 cites W1970609700 @default.
• W2170816474 cites W1981273749 @default.
• W2170816474 cites W1983815576 @default.
• W2170816474 cites W1993482422 @default.
• W2170816474 cites W2024571096 @default.
• W2170816474 cites W2026889435 @default.
• W2170816474 cites W2034408226 @default.
• W2170816474 cites W2037020524 @default.
• W2170816474 cites W2050664844 @default.
• W2170816474 cites W2068694430 @default.
• W2170816474 cites W2071472322 @default.
• W2170816474 cites W2076475992 @default.
• W2170816474 cites W2084710830 @default.
• W2170816474 cites W2092377833 @default.
• W2170816474 cites W2104258246 @default.
• W2170816474 cites W2110948955 @default.
• W2170816474 cites W2112233991 @default.
• W2170816474 cites W2116315322 @default.
• W2170816474 cites W2118857141 @default.
• W2170816474 cites W2123412381 @default.
• W2170816474 cites W2143958400 @default.
• W2170816474 cites W2413783447 @default.
• W2170816474 cites W4236694652 @default.
• W2170816474 cites W4243121607 @default.
• W2170816474 cites W4243245596 @default.
• W2170816474 cites W4246405704 @default.
• W2170816474 cites W4248069461 @default.
• W2170816474 cites W4252099292 @default.
• W2170816474 cites W4256018009 @default.
• W2170816474 doi "https://doi.org/10.2337/diabetes.50.8.1735" @default.
• W2170816474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11473032" @default.
• W2170816474 hasPublicationYear "2001" @default.
• W2170816474 type Work @default.
• W2170816474 sameAs 2170816474 @default.
• W2170816474 citedByCount "42" @default.
• W2170816474 countsByYear W21708164742012 @default.
• W2170816474 countsByYear W21708164742014 @default.
• W2170816474 countsByYear W21708164742015 @default.
• W2170816474 countsByYear W21708164742016 @default.
• W2170816474 countsByYear W21708164742020 @default.
• W2170816474 crossrefType "journal-article" @default.
• W2170816474 hasAuthorship W2170816474A5005436471 @default.
• W2170816474 hasAuthorship W2170816474A5038398583 @default.
• W2170816474 hasAuthorship W2170816474A5038424501 @default.
• W2170816474 hasAuthorship W2170816474A5057008464 @default.
• W2170816474 hasAuthorship W2170816474A5062927758 @default.
• W2170816474 hasAuthorship W2170816474A5066701655 @default.
• W2170816474 hasAuthorship W2170816474A5070865625 @default.
• W2170816474 hasAuthorship W2170816474A5084625995 @default.
• W2170816474 hasBestOaLocation W21708164741 @default.
• W2170816474 hasConcept C105795698 @default.
• W2170816474 hasConcept C112672928 @default.
• W2170816474 hasConcept C122048520 @default.
• W2170816474 hasConcept C126322002 @default.
• W2170816474 hasConcept C134018914 @default.
• W2170816474 hasConcept C159654299 @default.
• W2170816474 hasConcept C163764329 @default.
• W2170816474 hasConcept C165220095 @default.
• W2170816474 hasConcept C203014093 @default.
• W2170816474 hasConcept C2779234561 @default.
• W2170816474 hasConcept C2779306644 @default.
• W2170816474 hasConcept C2781232474 @default.
• W2170816474 hasConcept C33923547 @default.
• W2170816474 hasConcept C54355233 @default.
• W2170816474 hasConcept C555293320 @default.
• W2170816474 hasConcept C71924100 @default.
• W2170816474 hasConcept C86803240 @default.
• W2170816474 hasConceptScore W2170816474C105795698 @default.
• W2170816474 hasConceptScore W2170816474C112672928 @default.
• W2170816474 hasConceptScore W2170816474C122048520 @default.
• W2170816474 hasConceptScore W2170816474C126322002 @default.
• W2170816474 hasConceptScore W2170816474C134018914 @default.
• W2170816474 hasConceptScore W2170816474C159654299 @default.
• W2170816474 hasConceptScore W2170816474C163764329 @default.
• W2170816474 hasConceptScore W2170816474C165220095 @default.
• W2170816474 hasConceptScore W2170816474C203014093 @default.
• W2170816474 hasConceptScore W2170816474C2779234561 @default.
• W2170816474 hasConceptScore W2170816474C2779306644 @default.
• W2170816474 hasConceptScore W2170816474C2781232474 @default.
• W2170816474 hasConceptScore W2170816474C33923547 @default.
• W2170816474 hasConceptScore W2170816474C54355233 @default.
• W2170816474 hasConceptScore W2170816474C555293320 @default.
• W2170816474 hasConceptScore W2170816474C71924100 @default.
• W2170816474 hasConceptScore W2170816474C86803240 @default.
• W2170816474 hasIssue "8" @default.

• next